Neuren Pharmaceuticals (ASX:NEU) Eyes Overseas Growth, Is The Valuation Upside Still There?

Simply Wall St.10-18

Neuren Pharmaceuticals (ASX:NEU) has drawn fresh attention after outlining plans to extend its neurology drug portfolio into Canada, Europe, and Japan, with the aim of building new revenue streams and...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2676540469?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6121000-choice2-card/1788952923351","is_english":true,"pubTime":"2026-10-18 00:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2676540469","market":"nz","top_or_hot":-1,"title":"Neuren Pharmaceuticals (ASX:NEU) Eyes Overseas Growth, Is The Valuation Upside Still There?","media":"Simply Wall St.","content":"<div>\n<p>Neuren Pharmaceuticals (ASX:NEU) has drawn fresh attention after outlining plans to extend its neurology drug portfolio into Canada, Europe, and Japan, with the aim of building new revenue streams and...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/neuren-pharmaceuticals-asxneu-eyes-overseas-growth-is-the-va\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neuren Pharmaceuticals (ASX:NEU) Eyes Overseas Growth, Is The Valuation Upside Still There?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeuren Pharmaceuticals (ASX:NEU) Eyes Overseas Growth, Is The Valuation Upside Still There?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-10-18 00:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/neuren-pharmaceuticals-asxneu-eyes-overseas-growth-is-the-va><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Neuren Pharmaceuticals (ASX:NEU) has drawn fresh attention after outlining plans to extend its neurology drug portfolio into Canada, Europe, and Japan, with the aim of building new revenue streams and...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/neuren-pharmaceuticals-asxneu-eyes-overseas-growth-is-the-va\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NEU","symbol_name":"NewMarket","start_time":0,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/neuren-pharmaceuticals-asxneu-eyes-overseas-growth-is-the-va","article_id":"2676540469","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6121000-choice2-card/1788952923351"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/neuren-pharmaceuticals-asxneu-eyes-overseas-growth-is-the-va","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2676540469","pubTimestamp":1792254628,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Neuren Pharmaceuticals (ASX:NEU) has drawn fresh attention after outlining plans to extend its neurology drug portfolio into Canada, Europe, and Japan, with the aim of building new revenue streams and potentially securing higher royalty rates.\nAt a recent share price of A$20.21, Neuren Pharmaceuticals has seen a 5.32% 1 day share price return and a 19.09% 90 day share price return, while the 1 year total shareholder return is slightly negative and the 5 year total shareholder return is very...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"NEU":"NewMarket","NEU.AU":"NEUREN PHARMACEUTICALS LTD","BK7096":"制药","BK7508":"医药生物股","BK4109":"特种化学制品"},"translate_title":"Neuren Pharmaceuticals (ASX:NEU) 着眼海外增长，估值上升空间还在吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NEU.AU":1.5,"NEU":1.5},"content_text":"Neuren Pharmaceuticals (ASX:NEU) has drawn fresh attention after outlining plans to extend its neurology drug portfolio into Canada, Europe, and Japan, with the aim of building new revenue streams and potentially securing higher royalty rates. At a recent share price of A$20.21, Neuren Pharmaceuticals has seen a 5.32% 1 day share price return and a 19.09% 90 day share price return, while the 1 year total shareholder return is slightly negative and the 5 year total shareholder return is very large. This suggests that longer term holders have still been well rewarded as sentiment improves around its international rollout plans. Scan other rare-disease and neurology-focused biotechs that may be primed for similar international momentum by starting with our hand-picked 15 high quality undiscovered gems tied to strong underlying fundamentals. After a sharp swing higher on international hopes, Neuren Pharmaceuticals now asks a simple question of new capital: Does the current price still leave enough upside to justify the clinical and rollout risks ahead? AdvertisementMost Popular Narrative: 23% Undervalued Neuren Pharmaceuticals is trading at A$20.21 against a narrative fair value of A$26.11, which frames the stock as attractively priced relative to that estimate while still reminding investors that the story hinges on rare-disease execution and royalty durability.  Biotech companies are always something of a risk. Drug trials can require years of upfront investment, with no guarantee of a positive outcome. Therefore, small pharmaceutical companies that already have an income stream but also have drugs in the later stages of clinical trials can be worth investigating. As such, Neuren Pharmaceuticals (ASX: NEU) is the subject of today’s deep dive.  See why 1 investors see Neuren Pharmaceuticals as 23% undervalued. According to Robbo, the narrative rests on Neuren Pharmaceuticals combining an existing A$64.6 million royalty stream in 2025 with late stage programs like NNZ-2591. All of this is supported by a cash balance of about A$296 million as of 31 December 2025 that reduces reliance on fresh equity raises. That mix of current income, rare disease focus and a self funded pipeline is what underpins the A$26.11 fair value view and the conclusion that the shares trade at a discount to that narrative today. Result: Fair Value of A$26.11 (UNDERVALUED) Still, Neuren Pharmaceuticals faces real pressure points. If DAYBUE royalties disappoint or NNZ-2591 stumbles in Phase 3, either outcome could quickly re-rate the story. Find out about the key risks to this Neuren Pharmaceuticals narrative. Another Take On Neuren Pharmaceuticals: Expensive On Earnings The narrative fair value of A$26.11 paints Neuren Pharmaceuticals as attractively priced, yet the earnings based view tells a different story. At a P/E of 126.5x versus 21.6x for the global pharmaceuticals group, the stock carries a heavy valuation premium that investors cannot ignore. The gap is just as wide against peers on this metric, where the average sits at 25.6x, and even the estimated fair ratio of 53.9x is less than half Neuren Pharmaceuticals' current level. That kind of stretch can work for you if the pipeline delivers, but what if expectations slip before earnings catch up. For a closer look at how this earnings multiple compares across sectors and peers, review the valuation breakdown and see what the numbers imply for risk and potential return See what the numbers say about this price — find out in our valuation breakdown. ASX:NEU P/E Ratio as at Oct 2026Next Steps Sentiment around Neuren Pharmaceuticals is clearly mixed, with real upside hopes sitting alongside meaningful execution questions, so move quickly and stress test the numbers yourself. To weigh both sides of the argument in one place, start with the 3 key rewards and 2 important warning signs. Looking for more investment ideas beyond Neuren Pharmaceuticals? Do not stop with one opportunity. Broaden your watchlist with focused ideas that match different risk levels and income goals using the Simply Wall St Screener.  Target potential mispricing by scanning for quality companies that still trade below their estimated value through the 4 high quality undervalued stocks. Lock in income ideas by hunting for established businesses that offer robust payout potential using the 4 dividend fortresses. Dial down volatility by filtering for businesses with resilient financial profiles through the 6 resilient stocks with low risk scores.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Neuren Pharmaceuticals might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2676540469","isCrawlerRequest":true}